

Review Form 1.7

Journal Name:	Asian Journal of Immunology
Manuscript Number:	Ms_AJI_96265
Title of the Manuscript:	Burden of Autoimmune Disorders; An updated Review
Type of the Article	Review

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalaji.com/index.php/AJI/editorial-policy>)

Review Form 1.7

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p> <p>1. Is the manuscript important for scientific community? (Please write few sentences on this manuscript)</p> <p>2. Is the title of the article suitable? (If not please suggest an alternative title)</p> <p>3. Is the abstract of the article comprehensive?</p> <p>4. Are subsections and structure of the manuscript appropriate?</p> <p>5. Do you think the manuscript is scientifically correct?</p> <p>6. Are the references sufficient and recent? If you have suggestion of additional references, please mention in the review form. <u>(Apart from above mentioned 6 points, reviewers are free to provide additional suggestions/comments)</u></p>	<p>1: Yes 2: Yes 3: Yes 4: As I mentioned below, more recent targeting therapy, molecular therapy and cytokine/immune system dependent therapy would be described under newer subtitle. 5: Yes 6: Yes</p>	
<p>Minor REVISION comments</p> <p>1. Is language/English quality of the article suitable for scholarly communications?</p>		
<p>Optional/General comments</p>	<p>The author carefully presents a comprehensive review of autoimmune diseases, from the basic breakdown of self-tolerance to clinical events. The fundamentals are well summarized, and it is felt that this is a good review. However, the following points may need to be revised. It is odd that there are no references to Tables 1-3 or Figure 1 in the text. For Table 1 and Figure 1, the titles of those tables and figures are marked with the citation numbers, but are the copyrights protected? In the last chapter, there is a section on "New Insights," but in fact, even in the tables for each disease, these novel therapies such as antibody therapy, molecular targeted therapy, and therapy against cytokines - in other words, nowadays, the authors are trying to target molecules in the well-described T cells, B cells and peripheral permissive cells. In other words, are we not now seeing the attempts at therapies that target molecules in the T-cell, B-cell, and peripheral tolerance that the author has so well described? I would like to see a more in-depth discussion of this point, and mention the specific diseases for which many attempts are being made.</p>	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Are there ethical issues in this manuscript?</p>	<p><i>(If yes, Kindly please write down the ethical issues here in details)</i></p>	

Reviewer Details:

Name:	Takemi Otsuki
Department, University & Country	Kawasaki Medical School, Japan